As of Nov 19, 2026, 1 of 2 active firms rate ATRA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ATRA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.13 – $-0.13 · 1 analysts
Next period, 1 analysts expect Atara Biotherapeutics Inc to earn $-0.13 a share (range $-0.13 – $-0.13), versus — a year earlier. Full-year consensus is $-0.87, growing to $2.56 the year after.
REVENUE · NEXT QUARTER
$700.0K
Range $700.0K – $700.0K · 1 analysts · -83% YoY
Revenue is expected to reach $700.0K (range $700.0K – $700.0K), -83.0% year-over-year. Full-year consensus is $3.5M, rising to $40.9M next year.
Top analysts covering Atara Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ATRA.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Neutral
No targeton ATRA
Overall win rate
42%
+ Follow
#2
John Newman
Canaccord Genuity · Rank #538
Buy
$13.00+87.9% to target
Overall win rate
31%
+ Follow
#3
IZ
Ilya Zubkov
Freedom Broker
Neutral
$10.00+44.5% to target
Coverage
—
+ Follow
#4
IZ
Ilya Zubkov
Freedom Capital Markets
Neutral
$10.00+44.5% to target
Coverage
—
+ Follow
#5
TB
Tony Butler
Rodman & Renshaw
Buy
$25.00+261.3% to target
Coverage
—
+ Follow
ATRA stock forecast FAQ
What is ATRA's average 12-month price target?+
The 2 active firms with a live target average $11.50 for Atara Biotherapeutics Inc over the next 12 months, ranging from a $13.00 high to a $10.00 low, as of Nov 19, 2026.
Is ATRA stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ATRA?+
The Street-high target is $13.00 (Canaccord Genuity), and the Street-low is $10.00 (Freedom Broker). The average of all 2 active-firm targets is $11.50.
How many active Wall Street firms cover ATRA?+
2 active firms have a recognized rating on Atara Biotherapeutics Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ATRA?+
Among analysts who currently cover ATRA, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #215). Their current call is Neutral.
What is Atara Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.13 – $-0.13) across 1 analysts. Full-year EPS is projected at $-0.87, rising to $2.56 the following year.
How much revenue is Atara Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $700.0K (range $700.0K – $700.0K). Full-year revenue is projected at $3.5M, growing to $40.9M next year.
Have analysts been upgrading or downgrading ATRA lately?+
As of Nov 19, 2026, 1 of 2 active firms rate ATRA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ATRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.